Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement-Reference-Cited by-同舟云学术

Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement

Published:2022-03-09 Issue:3 Volume:40 Page:332-340
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Ferrero S.¹²^ORCID,Gentile Massimo³,Laurenti Luca⁴,Mauro Francesca Romana⁵,Martelli Maurizio⁵,Sportoletti Paolo⁶^ORCID,Visco Carlo⁷^ORCID,Zinzani Pier Luigi⁸^ORCID,Tedeschi Alessandra⁹^ORCID,Varettoni M.¹⁰^ORCID

Affiliation:

1. Department of Molecular Biotechnologies and Health Sciences Division of Haematology University of Torino Torino Italy

2. AOU “Città della Salute e della Scienza di Torino” Torino Italy

3. UOC Ematologia AO Cosenza Cosenza Italy

4. Hematology Università Cattolica del Sacro Cuore Policlinico A Rome Italy

5. Hematology Department of Translational and Precision Medicine Sapienza University Rome Italy

6. Department of Medicine Institute of Hematology‐Centro di Ricerche Emato‐Oncologiche (CREO) University of Perugia Perugia Italy

7. Department of Medicine, Section of Hematology University of Verona Verona Italy

8. IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Università degli Studi Bologna Italy

9. Hematology Niguarda Cancer Center ASST Grande Ospedale Metropolitano Niguarda Milan Italy

10. Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2982

Reference58 articles.

1. MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

2. Diagnosis and Management of Waldenström Macroglobulinemia

3. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

4. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?;Expert Opinion on Investigational Drugs;2023-12-02

2. Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China;Frontiers in Immunology;2023-07-07

3. Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL” (regional Tuscan lymphoma network);Annals of Hematology;2023-02-03